Pear Therapeutics, Inc. announced on 18 November it launched its prescription digital therapeutics dubbed Somryst aimed to help patients 22 and older with chronic insomnia.
The Somryst app was the first product to receive US Food and Drug Administration clearance in March under the agency’s software precertification pilot program. The app delivers cognitive behavioral therapy...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?